HomeREGULATORY
REGULATORY

Japan’s 1st Conditional OK Might Come This Autumn for Pfizer’s Next-Gen ALK Inhibitor Lorlatinib
(Jun.13.2018)

Pfizer’s lorlatinib is the first candidate being reviewed by the Japanese health ministry under its conditional early drug approval system introduced last October, it was revealed on June 12, with the next-generation ALK tyrosine kinase inhibitor (TKI) now seen likely to win its blessing as early as this autumn ...
(LOG IN FOR FULL STORY)